Indian Council of Medical Research (ICMR) has advised that indiscriminate use of Convalescent Plasma therapy is not advisable for the treatment of the Covid-19 cases.
 

ICMR conducted an open-label phase II multicentre randomized controlled trial in India across 39 public and private hospitals on the use of convalescent plasma in the management of cases with moderate COVID-19 disease.
 

In the trial, it has been concluded that Convalescent Plasma therapy did not lead to a reduction in progression to severe Covid-19 or all-cause mortality in the group that received Convalescent Plasma therapy as compared to the group that did not receive the therapy.